Katrine Hass Rubin1, Dorte Glintborg2, Mads Nybo3, Bo Abrahamsen1,4, Marianne Andersen2. 1. OPEN-Odense Patient Data Explorative Network, Institute of Clinical Research, University of Southern Denmark, 5000 Odense C, Denmark. 2. Department of Endocrinology, Odense University Hospital, 5000 Odense C, Denmark. 3. Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, 5000 Odense C, Denmark. 4. Department of Medicine, Holbaek Hospital, 4300 Holbaek, Denmark.
Abstract
Objective: Polycystic ovary syndrome (PCOS) is associated with insulin resistance and obesity. Prospective population-based data regarding development and possible predictors of type 2 diabetes (T2D) in PCOS are limited. Design: National Patient Register-based study. Methods: Patients with PCOS [PCOS Denmark and embedded cohort, PCOS Odense University Hospital (OUH)] and a control population with no previous diagnosis of T2D. PCOS OUH (N = 1,162) included premenopausal women with PCOS and standardized clinical and biochemical examination. PCOS Denmark (N = 18,477) included women with PCOS in the Danish National Patient Register. Three age-matched controls were included per patient (N = 54,680). Main outcome: T2D events according to diagnosis codes and filled medicine prescriptions. Results: The median (quartiles) follow-up was 11.1 (6.9 to 16.0) years. The hazard ratio (HR) with 95% confidence interval (CI) for development of T2D in PCOS Denmark was HR = 4.0 (95% CI, 3.7 to 4.3; P < 0.001), and the total event rate of T2D was 8.0 per 1000 person years in PCOS Denmark vs 2.0 per 1000 person years in controls (P < 0.001). The median age at diagnosis of T2D was 31 (26 to 37) years in PCOS Denmark vs 35 (27 to 44) years in controls (P < 0.001). In multiple regression analyses, body mass index, glycated hemoglobin, fasting blood glucose, 2-hour blood glucose, homeostasis model assessment of insulin resistance, and triglycerides were positively associated with development of T2D, whereas higher number of births was negatively associated with development of T2D. Conclusion: The event rate of T2D was higher in PCOS compared with controls, and T2D was diagnosed at a younger age.
Objective: Polycystic ovary syndrome (PCOS) is associated with insulin resistance and obesity. Prospective population-based data regarding development and possible predictors of type 2 diabetes (T2D) in PCOS are limited. Design: National Patient Register-based study. Methods:Patients with PCOS [PCOS Denmark and embedded cohort, PCOS Odense University Hospital (OUH)] and a control population with no previous diagnosis of T2D. PCOS OUH (N = 1,162) included premenopausal women with PCOS and standardized clinical and biochemical examination. PCOS Denmark (N = 18,477) included women with PCOS in the Danish National Patient Register. Three age-matched controls were included per patient (N = 54,680). Main outcome: T2D events according to diagnosis codes and filled medicine prescriptions. Results: The median (quartiles) follow-up was 11.1 (6.9 to 16.0) years. The hazard ratio (HR) with 95% confidence interval (CI) for development of T2D in PCOS Denmark was HR = 4.0 (95% CI, 3.7 to 4.3; P < 0.001), and the total event rate of T2D was 8.0 per 1000 person years in PCOS Denmark vs 2.0 per 1000 person years in controls (P < 0.001). The median age at diagnosis of T2D was 31 (26 to 37) years in PCOS Denmark vs 35 (27 to 44) years in controls (P < 0.001). In multiple regression analyses, body mass index, glycated hemoglobin, fasting blood glucose, 2-hour blood glucose, homeostasis model assessment of insulin resistance, and triglycerides were positively associated with development of T2D, whereas higher number of births was negatively associated with development of T2D. Conclusion: The event rate of T2D was higher in PCOS compared with controls, and T2D was diagnosed at a younger age.
Authors: Julie Aarestrup; Dorthe C Pedersen; Peter E Thomas; Dorte Glintborg; Jens-Christian Holm; Lise G Bjerregaard; Jennifer L Baker Journal: Obes Facts Date: 2021-05-12 Impact factor: 3.942
Authors: Guadalupe Navarro; Camille Allard; Jamie J Morford; Weiwei Xu; Suhuan Liu; Adrien Jr Molinas; Sierra M Butcher; Nicholas Hf Fine; Manuel Blandino-Rosano; Venkata N Sure; Sangho Yu; Rui Zhang; Heike Münzberg; David A Jacobson; Prasad V Katakam; David J Hodson; Ernesto Bernal-Mizrachi; Andrea Zsombok; Franck Mauvais-Jarvis Journal: JCI Insight Date: 2018-06-21
Authors: Panagiotis Anagnostis; Rodis D Paparodis; Julia K Bosdou; Christina Bothou; Djuro Macut; Dimitrios G Goulis; Sarantis Livadas Journal: Endocrine Date: 2021-06-26 Impact factor: 3.633
Authors: Siew S Lim; Samantha K Hutchison; Emer Van Ryswyk; Robert J Norman; Helena J Teede; Lisa J Moran Journal: Cochrane Database Syst Rev Date: 2019-03-28
Authors: Amanda E Bries; Joseph L Webb; Brooke Vogel; Claudia Carrillo; Aileen F Keating; Samantha K Pritchard; Gina Roslan; Joshua W Miller; Kevin L Schalinske Journal: J Nutr Date: 2021-06-01 Impact factor: 4.798
Authors: Cecily V Bishop; Diana Takahashi; Emily Mishler; Ov D Slayden; Charles T Roberts; Jon Hennebold; Cadence True Journal: Hum Reprod Date: 2021-01-25 Impact factor: 6.918